Held by 4 specialist biotech funds
High Convergence# Signal Note: OrbiMed Initiates $323.7M LLY Position OrbiMed's new 301,200-share position in Eli Lilly signals conviction in LLY's near-term pipeline catalysts, likely centered on GLP-1 obesity franchise expansion (tirzepatide) and potential label extensions, which face competitive pressure from Novo Nordisk but maintain differentiated efficacy data.
AI analyst context — unlock full analysis
# Signal Note: Driehaus initiates LLY position Driehaus Capital's new $884K position in Eli Lilly signals conviction in the company's GLP-1 franchise momentum, particularly Mounjaro (tirzepatide) in diabetes and obesity, which is driving near-term revenue acceleration and margin expansion. The timing aligns with ongoing label expansion studies and competitive positioning in the high-growth incretin market, where LLY has demonstrated superior efficacy data versus semaglutide. For a growth-focused manager, this entry suggests confidence in sustained earnings revisions through 2024-2025.
+ 2 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial